Clinical trial
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have…
NCT00453310 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00453310 |
|---|---|
| Title | Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment |
| Official title | A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor |
| Intervention type | Drug |
| Interventions | sunitinib malate |
| Enrollment | 10 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Mar 28, 2007 |
| Last update posted | Oct 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: